| dbo:abstract
|
- Dimitri Azar M.D. (born 1959) is an American ophthalmologist, professor, and businessman who leads Twenty Twenty Therapeutics, a joint venture established by Santen and Verily. Dr. Azar has held roles at Novartis and Verily, Alphabet's Life sciences research organization. He served as dean of the College of Medicine at the University of Illinois at Chicago (UIC) from 2011 to 2018. (en)
|
| dbo:almaMater
| |
| dbo:institution
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 18025 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:almaMater
|
- American University of Beirut, Lebanon; Wilmer Eye Institute, Johns Hopkins Hospital School of Medicine; Massachusetts Eye and Ear Infirmary, Harvard Medical School; University of Chicago Booth School of Business (en)
|
| dbp:birthDate
| |
| dbp:date
| |
| dbp:fields
| |
| dbp:url
| |
| dbp:wikiPageUsesTemplate
| |
| dbp:workplaces
|
- University of Illinois at Chicago; American Ophthalmological Society; Chicago Ophthalmological Society; Chicago Medical Society; Association of Research in Vision and Ophthalmology; Verily; Verb Surgical Inc; Tear Film and Ocular Surface Society; Novartis (en)
|
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Dimitri Azar M.D. (born 1959) is an American ophthalmologist, professor, and businessman who leads Twenty Twenty Therapeutics, a joint venture established by Santen and Verily. Dr. Azar has held roles at Novartis and Verily, Alphabet's Life sciences research organization. He served as dean of the College of Medicine at the University of Illinois at Chicago (UIC) from 2011 to 2018. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
